title: [Drug treatment of hyperlipoproteinemias].
abstract: If by regulation of the ideal weight, by type-optimated diet and physical conditioning we do not succeed in a satisfying regulation of the hyperlipoproteinaemias, the indication to the medicamentous therapy is given. For the treatment of type IIa in the first place cholestyramine and essential phospholipids are taken into consideration, in unsatisfying effect the combination cholestyramin-regadrin. For the types IIb-V regadrin and preparations of nicotinic acid are the remedies of choice. In an unsatisfying decrease of lipids the combination regadrin-nicotinic acid and regadrin-buformin-respectively, should be used. To what extent by a medicamentous decrease of lipids a primary or secondary prevention of ischaemic vascular diseases is possible, at present cannot be answered definitively.
mesh_terms: D002779:Cholestasis / Q000139:chemically induced; D002792:Cholestyramine Resin / Q000009:adverse effects / Q000627:therapeutic use; D002994:Clofibrate / Q000009:adverse effects / Q000627:therapeutic use; D003084:Colestipol / Q000009:adverse effects / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000139:chemically induced; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008297:Male; D009539:Nicotinic Acids / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D009539:Nicotinic Acids; D002792:Cholestyramine Resin; D002994:Clofibrate; D003084:Colestipol
vernacular_title: Medikamentöse Behandlung von Hyperlipoproteinämien.